The current review focuses on the neonatal presentation of disorders of sex development, summarize the current approach to the evaluation of newborns and describes recent advances in understanding of underlying genetic aetiology of these conditions.
INTRODUCTION
Disorders of sex development (DSDs) is a collective term for a group of relatively rare congenital conditions that are associated with an alteration in chromosomal, gonadal, or anatomic sex [1] . Atypical genitalia at birth are the commonest manifestation of DSD and in epidemiological studies, this may occur in approximately 1 in 300 births [2] , although true genital ambiguity requiring comprehensive medical assessment may only occur in 1 in 4500 live births [3] . Registry-based studies show that over three quarters of cases of atypical genitalia present with a hypospadias [2] , have a 46,XY karyotype [4] and are raised as boys [5] . In addition, it is likely that more infants with this presentation will be raised as boys in the future [6] and long-term management of these boys will require a detailed knowledge of the underlying pathological diagnosis [7] . However, systematic and thorough investigations in these boys with a 46,XY karyotype reveal endocrine abnormalities in only a quarter of cases whilst molecular genetic assessment may reveal a molecular genetic cause in almost half, depending on the extent of genetic analysis [8, 9 && ,10 && ]. Thus, as a group, 46,XY neonates with atypical genitalia represent the greatest challenge in terms of diagnosis and long-term management. Whilst clinical guidelines stress the importance of an integrated multidisciplinary approach for the assessment and management of these conditions [1,11 && ], rapid advances in genetic knowledge as well as technology are altering the stepwise investigational strategies that have traditionally been employed in this field [12, 13] . This review will focus on the neonatal presentation of DSD and summarize the current approach to the evaluation of these children.
A thorough initial evaluation of an affected newborn including a family history, pregnancy history and an assessment of feeding, electrolyte and blood sugar abnormalities is an important first step. Unlike the cases that present late, when the diagnosis of DSD is suspected by a disorder of puberty, in neonates the classical presentation includes the presence of atypical genitalia and, in some cases, associated anomalies. Features of atypical genitalia include clitoromegaly or posterior labial fusion in genitalia that are otherwise 'apparently female' and bilateral cryptorchidism, microphallus, hypospadias, or bifid scrotal folds in an otherwise 'apparently male' infant [1] . In addition to a thorough examination and palpation of the gonads, the phenotype of the involved neonate can be more comprehensively assessed by using scoring systems. Although the Prader scale is primarily employed to assess the extent of virilization of the female genitalia in congenital adrenal hyperplasia (CAH), the external masculinization score (EMS) is often used as a standardized tool to guide the need for investigations [11 && ,14] . However, such objective scores as well as the appearance of the external genitalia do not seem to play a critical role in guiding sex of rearing as evident from registry-based studies [6, 15] .
Infants with suspected DSD may often have extragenital anomalies and in 46,XY cases, cardiac and neurological malformations may be identified in 20% of cases [4] . However, the most common associated condition is being small for gestational age (SGA), which has been reported in almost quarter of cases [4] . The highest frequency of concomitant conditions was in those with gonadal development disorders. Although the occurrence of extragenital abnormalities may be associated with the severity of under-masculinization [16] , no correlation was made between the presence of variants in androgen receptor gene (AR) and SGA [17] . In fact, the presence of SGA is more likely in those who may have been labelled as PAIS (partial androgen insensitivity syndrome) on phenotype but do not have a confirmed diagnosis on AR analysis [17] . Thus, initial evaluation and further comprehensive clinical assessment can guide complementary diagnostic procedures.
CAUSES OF 46,XY DSD
The causes of DSD should be considered through the prism of the pathogenesis of condition. According to the classification proposed in Chicago in 2005 [1] , there are three major subgroups of 46,XY DSDs: disorders of gonadal development, disorders of androgen synthesis and androgen action. The aetiology of DSD is multifactorial and the study of molecular mechanisms of sex development have revealed several possible candidate genes as well as other adverse environmental factors.
DISORDERS OF GONADAL DEVELOPMENT
46,XY disorders of gonadal development include the complete gonadal dysgenesis (CGD) and partial gonadal dysgenesis (PGD) that are characterized by a variable presence of M€ ullerian and Wolffian ducts, variably functioning gonads and a spectrum of external genitalia from normal male genitalia to normal female genitalia. The development of the gonads throughout embryogenesis from the urogenital ridge is influenced by signalling pathways that lead to changing expression of genes involved [18] . The first testis-determining factor, the sex determining region Y (SRY), was discovered in 1990 [19] and to date, over 90 different mutations within this gene have been identified within the high mobility group (HMG) box domain [20] as well as beyond [21] . SRY variants cause CGD in less than 15% of cases [22] whereas the prevalence of this condition is only 1.2 per 100 000 [23] . A number of other genes have also been implicated in disorders of gonadal development, such as SOX9, NR5A1, DAX1 (NR0B1), DHH, WT1, WNT4, GATA4, MAP3K1, DMRT1 and WWOX (Table 1) . SOX9 variants were detected in patients with gonadal dysgenesis and concomitant bone abnormalities because of the lack of chondrocyte-specific enhancer activity [78] . Although a
KEY POINTS
Neonates affected by DSD usually present with atypical genitalia and, in some cases, associated anomalies and require a thorough evaluation.
Evaluation of a neonate with suspected DSD requires a systematic approach with a focus on first-line investigations that ensure that the child is not at risk of any life-threatening events.
The aetiology of DSD is multifactorial and genetic abnormalities may be currently identifiable in around 50% of cases but this may depend on the extent of molecular genetic assessment.
Children and adults with DSD may be at risk of several comorbidities and a detailed knowledge of the underlying genetic abnormality may guide management. [31] . CD is an autosomal dominant disorder because of loss-of-function mutations in SOX9 [32] . Milder clinical variants of the disease and longer survival are typical for patients with translocation breakpoints [32] [33] [34] . Acampomelic dysplasia is a rare form of campomelic dysplasia, characterized by milder phenotype and absence of long bone curvature [31, 35] 46,XX testicular DSD or 46,XX ovotesticular DSD Interstitial chromosome duplications located around 600 kb upstream of SOX9 [36] Zinc finger protein, multitype 2 (FOG2; ZFPM2)
8q23.1 603693 46,XY PGD with congenital heart disease and bilateral clinodactyly of the fifth finger Altered FOG-2 expression because of de novo balanced t(8;10)(q23.1;q21.1) translocation [37] 46,XY CGD with bilateral clinodactyly of the fifth finger and no heart disease Single case of XY female with heterozygous c.1206T. A variant inherited from maternal grandmother [38] 46,XY PGD with mental retardation, congenital heart disease, and LangerÀGiedion syndrome De novo chromosomal translocation: 46,XY t(8;18)(q22; q21) [39] 46,XY PGD and autistic spectrum disorder 46,XY bilateral anorchia and microphallus One case reported, a novel heterozygous partial loss of function mutation (V355M) in NR5A1was reported in a boy with a micropenis and testicular regression syndrome [46] 46,XY hypospadias Single case with isolated glandular hypospadias and normal testis within the scrotum [47] 46,XX primary adrenal failure One case reported, heterozygous p.Arg255Leu mutation with apparently normal functioning ovaries in a 14-month-old girl without further follow-up description [48] 46,XX primary ovarian insufficiency Phenotypes ranging from ovarian dysgenesis to premature ovarian failure reported [49, 50] mice exhibits an absence of kidneys, ureters, gonads, and genital tracts [75] . Several cases of 10q microdeletion encompassing EMX2 associated with genital anomalies have been reported [76, 77] DSD, disorder of sex development; CGD, complete gonadal dysgenesis; HMG, high mobility group; PGD, partial gonadal dysgenesis; MIM, Mendelian Inheritance in Man.
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small number of individuals were found to be carriers of variants in DHH, gonadal cancer was evident in almost 30% of them [60] and it was commonly associated with peripheral minifascicular neuropathy [61, 79, 80] . 46,XY PGD and CGD because of missense variants in WT1 were recognized in Denys Drash syndrome [81] and concurrent renal abnormalities [82] . NR5A1, encoding the SF-1 protein, plays a pivotal role in the development of gonads and steroidogenesis. Phenotypes associated with NR5A1 variants are highly diverse ranging from CGD with female external genitalia and M€ ullerian remnants, severe adrenal insufficiency [40] to isolated glandular hypospadias with intact adrenal steroidogenesis, normal male genitalia with infertility as well as normal gonadal function with progressive deterioration in gonadal function [51, 83] . Thus, dysregulation of genetic pathways responsible for sex determination and steroidogenesis determines the complexity of the phenotypes in 46,XY gonadal dysgenesis.
DISORDERS OF ANDROGEN SYNTHESIS
Disorders of androgen synthesis include luteinizing hormone receptor defects and defects in the testicular steroidogenesis pathway ( Table 2 ). The gonadal expression of human lutropinÀchoriogonadotropin receptor gene (LHCGR) is stimulated by placental human chorionic gonadotropin (hCG) during the foetal period and results in increased testosterone synthesis and subsequent development of genitalia. Inactivating variants in LHCGR lead to Leydig cell insensitivity to hCG and luteinizing hormone stimulation [103] can lead to a variable level of undermasculinization including completely female external genitalia and a blind-ended vagina [104] . Androgen synthesis is impaired in cases of congenital hypogonadotropic hypogonadism and Kallman's syndrome, and although this has usually been described in association with microphallus and cryptorchidism at birth [105] , more recent reports suggest that variants in a number of hypogonadotropic hypogonadism genes have identified in cases of hypospadias [9 && ]. Among all forms of 46,XY DSD, the genetic causes are clear for those presenting with enzyme deficiencies of 'classic' androgen biosynthesis pathways, including 17b-hydroxysteroid dehydrogenase type 3 (17b-HSD3) or 3b-hydroxysteroid dehydrogenase type 2 (3b-HSD2) deficiency. Whilst the deficit of 17b-HSD3 may interfere only with androgen production and more often is detected because of virilization at puberty, 3b-HSD2 may affect all steroidogenic pathways and, therefore, results in severe salt-wasting and nonsalt-wasting forms of CAH and ambiguous genitalia in affected boys [106, 107] . Over 45 causative mutations have been reported in HSD17B3 and the prevalence has been reported about 1 per 150 000 [108] . The conversion of testosterone to dihydrotestosterone (DHT), the active androgen in peripheral target tissue, is regulated by the 'alternative' pathway and controlled by the members of the AKR1C family and 5a-reductase, type 1 enzyme encoded by SRD5A1. Splice site variants in AKR1C2 and AKR1C4 genes resulting in reduced function to about 10% of activity were reported by Fl€ uck et al. [102] in three previously described familial cases of 46,XY girls [109] . Among two known 5-alpha-reductase enzymes only expression of type 2 was detectable in different androgensensitive tissues [110] and over 70 missense mutations in SRD5A2 have been described as a cause of genital ambiguity in boys.
DISORDERS OF ANDROGEN ACTION
A resistance to androgen action in 46,XY has been defined as an androgen insensitivity syndrome (AIS), which has phenotypically consisted of complete (CAIS) and partial (PAIS) forms. The appearance of genitalia in PAIS may vary extensively from slightly atypical to almost female whereas CAIS is associated with completely female external genitalia which often results in a later presentation with primary amenorrhea in adolescent girls. Most genetic analyses reveal defects in both, DNA-binding and steroid-binding, functional domains of the coding region of AR as a cause of this condition [111] [112] [113] that results in reduced androgen-binding activity. The AR locus is positioned on the X chromosome between Xq13 and Xp11 [114] , and, therefore, the majority of variants are maternally inherited whilst about 30% are de novo [115] . Although the presence of inactivating variants in AR may be evident in over 80% of girls and women with CAIS [15, 116] , AR variants in PAIS are much rarer. It is possible that in some cases, these variants may exist beyond the AR-coding region [117 && ]. It is also possible that androgen insensitivity may be because of a defect in the coactivators binding process to the AR [118]. However, there is a need to explore more effective methods of selecting cases that may display androgen insensitivity. Whilst in the past, this has involved assessment of AR binding in genital skin fibroblasts [119, 120] or measurement of circulating androgen responsive proteins in response to androgen stimulation [121, 122] , in the future it may be possible to use other methods such as measurement of apolipoprotein D in genital skin fibroblasts [117 && ] or assessment of changes in an androgen responsive transcriptome within Human aldo-keto reductases AKR1C2 and AKR1C4 are involved in the synthesis of 5a-pregnane-3,20-dione and 3a-hydroxy-5a-pregnane-20-one, a precursor of androsterone and DHT [101] .
Heterozygous missense variants in the coding region of AKR1C2 and a splicing variant in AKR1C4 were reported in a 46,XY female individuals [102] circulating polymorphonuclear blood cells [123 && ]. Variants in several other genes, such as INSL3, AMH, AMHR2, MAMLD1, TAC3, WDR11, TACR3, HS6ST1, CHD7, may also contribute to DSD [124] .
Although the number of studies emphasizing the role of endocrine-disrupting chemicals in genital malformations have increased over the last decade, the epidemiological data are scarce [125] . Nevertheless, one study highlighted the risk of contact with hair cosmetics and veterinary insecticides during pregnancy [126] . Other studies concentrating on organic solvents have indicated the association between urinary tract anomalies including hypospadias and cryptorchidism in babies and maternal exposure to these chemicals [127, 128] . Rodent studies have reported a negative impact of the phthalate exposure on rat genital development [129] [130] [131] . Whilst the influence of environmental and occupational risk factors on prenatal gonadal and genital development cannot be underestimated, there is a need for further studies to understand the true risk that is posed by these environmental disruptors.
WHAT SHOULD BE DONE IMMEDIATELY
After initial examination, infants with suspected DSD require an extended clinical, biochemical, and genetic evaluation soon after birth in order to exclude life-threatening conditions and confirm the karyotype. The initial diagnostic approach to an infant with suspected DSD has been outlined in detail [11
&&
]. As girls with CAH will more likely be severely virilized, it is important to measure serum plasma glucose, serum 17-hydroxyprogesterone (17-OHP) and serum concentration of sodium, potassium, chloride and urea. However, biochemical changes may only emerge after the third or fourth days of life for 17-OHP and electrolytes. Serum level of AMH and ultrasound examination can give an insight about the presence of testicular tissue and the latter can clarify the presence of M€ ullerian structures. A rapid quantitative fluorescent PCR should effectively detect Y chromosome fragments [132, 133] 
LIKELIHOOD OF FINDING AN ABNORMALITY
Although a number of environmental exposures have been described as risk factors for genital malformations, the vast majority of aetiological studies in the field of DSD are being conducted to discover causative variants. Confirming a definitive diagnosis is one of the crucial diagnostic aspects for such type of conditions in order to predict comorbidities and long-term outcomes [134, 135] . However, despite the existence of a wide range techniques available and a desire of clinicians to use them on a routine basis, the decision to perform these tests was reported to be restricted by geography or availability of the test, when the more extended analyses were accessible only through the research projects [13] . Although one study reported a diagnostic yield of 64% [136] , most do not demonstrate such a high level of diagnostic yield. In a recent study published by Nixon et al. [10 && ], copy number variants (CNVs) identified using Comparative Genomic Hybridization or single gene variants detected by Sanger sequencing of seven DSD-associated genes was present in about 50% of the cohort of boys with suspected DSD. Interestingly, despite the presence of a genetic abnormality, almost half of these patients had normal endocrine test results. Furthermore, the detection of CNV may be higher when investigating those with associated abnormalities. Another study reached a diagnostic yield of genetic abnormalities of almost 50% in 46,XY DSD using a massive parallel sequencing technology [9 && ]. Currently, the known prevalence of genetic findings in XY DSD patients may principally depend on the extent of molecular genetic assessment [10 && ]. High-throughput NGS technology has become available in many clinical centres and this may lead to a higher diagnostic yield. However, it is likely that this will also place greater demands on careful and detailed phenotypic as well as bioinformatic analysis and will require close collaboration within a specialist multidisciplinary diagnostic team that consists of experts with a knowledge of the clinical field as well as complex biochemistry and molecular genetics.
CONCLUSION
In summary, DSD are a group of rare congenital conditions that commonly result in atypical appearance of genitalia or delayed/impaired puberty and an underlying causative diagnosis remain unclear in the majority of patients. In the long-term, children and adults with DSD may be at risk of several comorbidities and a clear aetiological diagnosis will guide management. To date, this diagnosis is not reached in over half of the cases of 46,XY DSD. Whilst it is likely that improved diagnostic resources will bridge this gap in the future, the next challenge to the clinical community will be to show that such advances will result in and improvement in clinical care.
